Top

Published in:

01-12-2007 | Article

Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms

Authors: S. A. Schäfer, O. Tschritter, F. Machicao, C. Thamer, N. Stefan, B. Gallwitz, J. J. Holst, J. M. Dekker, L. M. t’Hart, G. Nijpels, T. W. van Haeften, H. U. Häring, A. Fritsche

Published in: Diabetologia | Issue 12/2007

Abstract

Aims/hypothesis

Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes and reduced insulin secretion. The transcription factor TCF7L2 is an essential factor for glucagon-like peptide-1 (GLP-1) secretion from intestinal L cells. We studied whether a defect in the enteroinsular axis contributes to impaired insulin secretion in carriers of TCF7L2 polymorphisms.

Methods

We genotyped 1,110 non-diabetic German participants for five single nucleotide polymorphisms in TCF7L2. All participants underwent an OGTT; GLP-1 secretion was measured in 155 participants. In 210 participants, an IVGTT combined with a hyperinsulinaemic–euglycaemic clamp was performed. In another 160 participants from the Netherlands and 73 from Germany, a hyperglycaemic clamp (10 mmol/l) was performed. In 73 German participants this clamp was combined with a GLP-1 infusion and an arginine bolus.

Results

The OGTT data confirmed that variants in TCF7L2 are associated with reduced insulin secretion. In contrast, insulin secretion induced by an i.v. glucose challenge in the IVGTT and hyperglycaemic clamp was not different between the genotypes. GLP-1 concentrations during the OGTT were not influenced by the TCF7L2 variants. However, GLP-1-infusion combined with a hyperglycaemic clamp showed a significant reduction in GLP-1-induced insulin secretion in carriers of the risk allele in two variants (rs7903146, rs12255372, p < 0.02).

Conclusions/interpretation

Variants of TCF7L2 specifically impair GLP-1-induced insulin secretion. This seems to be rather the result of a functional defect in the GLP-1 signalling in beta cells than a reduction in GLP-1 secretion. This defect might explain the impaired insulin secretion in carriers of the risk alleles and confers the increased risk of type 2 diabetes.

Available only for authorised users

Grant SF, Thorleifsson G, Reynisdottir et al (2006) Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 38:320–323PubMedCrossRef

Stumvoll M, Haring H (2002) The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes 51:2341–2347PubMedCrossRef

Schwanstecher C, Schwanstecher M (2002) Nucleotide sensitivity of pancreatic ATP-sensitive potassium channels and type 2 diabetes. Diabetes 51(Suppl 3):S358–S362PubMedCrossRef

Chandak GR, Janipalli CS, Bhaskar et al (2006) Common variants in the TCF7L2 gene are strongly associated with type 2 diabetes mellitus in the Indian population. Diabetologia 50:63–67PubMedCrossRef

Vliet-Ostaptchouk JV, Shiri-Sverdlov R, Zhernakova et al (2006) Association of variants of transcription factor 7-like 2 (TCF7L2) with susceptibility to type 2 diabetes in the Dutch Breda cohort. Diabetologia 50:59–62PubMedCrossRef

Saxena R, Gianniny L, Burtt et al (2006) Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diabetes 55:2890–2895PubMedCrossRef

Damcott CM, Pollin TI, Reinhart et al (2006) Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes in the Amish: replication and evidence for a role in both insulin secretion and insulin resistance. Diabetes 55:2654–2659PubMedCrossRef

Zhang C, Qi L, Hunter DJ et al (2006) Variant of transcription factor 7-like 2 (TCF7L2) gene and the risk of type 2 diabetes in large cohorts of U.S. women and men. Diabetes 55:2645–2648PubMedCrossRef

Florez JC, Jablonski KA, Bayley N et al (2006) TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 355:241–250PubMedCrossRef

10.

Scott LJ, Bonnycastle LL, Willer CJ et al (2006) Association of transcription factor 7-like 2 (TCF7L2) variants with type 2 diabetes in a Finnish sample. Diabetes 55:2649–2653PubMedCrossRef

11.

Reynisdottir I, Thorleifsson G, Benediktsson R et al (2003) Localization of a susceptibility gene for type 2 diabetes to chromosome 5q34-q35.2. Am J Hum Genet 73:323–335PubMedCrossRef

12.

Cauchi S, Meyre D, Dina C et al (2006) Transcription factor TCF7L2 genetic study in the French population: expression in human beta-cells and adipose tissue and strong association with type 2 diabetes. Diabetes 55:2903–2908PubMedCrossRef

13.

Helgason A, Palsson S, Thorleifsson G et al (2007) Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet 39:218–225PubMedCrossRef

14.

Yi F, Brubaker PL, Jin T (2005) TCF-4 mediates cell type-specific regulation of proglucagon gene expression by β-catenin and glycogen synthase kinase-3β. J Biol Chem 280:1457–1464PubMedCrossRef

15.

Fritsche A, Stefan N, Hardt E, Schutzenauer S, Haring H, Stumvoll M (2000) A novel hyperglycaemic clamp for characterization of islet function in humans: assessment of three different secretagogues, maximal insulin response and reproducibility. Eur J Clin Investig 30:411–418CrossRef

16.

Tripathy D, Wessman Y, Gullstrom M, Tuomi T, Groop L (2003) Importance of obtaining independent measures of insulin secretion and insulin sensitivity during the same test: results with the Botnia clamp. Diabetes Care 26:1395–1401PubMedCrossRef

17.

‘t Hart LM, Fritsche A, Rietveld I et al (2004) Genetic factors and insulin secretion: gene variants in the IGF genes. Diabetes 53(Suppl 1):S26–S30PubMedCrossRef

18.

Ruige JB, Dekker JM, Nijpels G et al (1999) Hyperproinsulinaemia in impaired glucose tolerance is associated with a delayed insulin response to glucose. Diabetologia 42:177–180PubMedCrossRef

19.

van Haeften TW, Dubbeldam S, Zonderland ML, Erkelens DW (1998) Insulin secretion in normal glucose-tolerant relatives of type 2 diabetic subjects. Assessments using hyperglycemic glucose clamps and oral glucose tolerance tests. Diabetes Care 21:278–282PubMedCrossRef

20.

Fritsche A, Stefan N, Hardt E, Haring H, Stumvoll M (2000) Characterisation of beta-cell dysfunction of impaired glucose tolerance: evidence for impairment of incretin-induced insulin secretion. Diabetologia 43:852–858PubMedCrossRef

21.

Stumvoll M, Fritsche A, Madaus et al (2001) Functional significance of the UCSNP-43 polymorphism in the CAPN10 gene for proinsulin processing and insulin secretion in nondiabetic Germans. Diabetes 50:2161–2163PubMedCrossRef

22.

Tschritter O, Stumvoll M, Machicao et al (2002) The prevalent Glu23Lys polymorphism in the potassium inward rectifier 6.2 (KIR6.2) gene is associated with impaired glucagon suppression in response to hyperglycemia. Diabetes 51:2854–2860PubMedCrossRef

23.

Olivier M, Chuang LM, Chang MS et al (2002) High-throughput genotyping of single nucleotide polymorphisms using new biplex invader technology. Nucleic Acids Res 30:e53PubMedCrossRef

24.

Deacon CF, Johnsen AH, Holst JJ (1995) Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952–957PubMedCrossRef

25.

Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462–1470PubMedCrossRef

26.

Papadopoulou S, Edlund H (2005) Attenuated Wnt signaling perturbs pancreatic growth but not pancreatic function. Diabetes 54:2844–2851PubMedCrossRef

27.

Hansen L, Deacon CF, Orskov C, Holst JJ (1999) Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9–36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140:5356–5363PubMedCrossRef

28.

D’Alessio DA, Sandoval DA, Seeley RJ (2005) New ways in which GLP-1 can regulate glucose homeostasis. J Clin Invest 115:3406–3408PubMedCrossRef

Title: Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms
Authors: S. A. Schäfer
O. Tschritter
F. Machicao
C. Thamer
N. Stefan
B. Gallwitz
J. J. Holst
J. M. Dekker
L. M. t’Hart
G. Nijpels
T. W. van Haeften
H. U. Häring
A. Fritsche
Publication date: 01-12-2007
Publisher: Springer-Verlag
Published in: Diabetologia / Issue 12/2007
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-007-0753-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Please log in to get access to this content

Other articles of this Issue 12/2007

The effect of birth order and parental age on the risk of type 1 and 2 diabetes among young adults

Brothers of women with polycystic ovary syndrome are characterised by impaired glucose tolerance, reduced insulin sensitivity and related metabolic defects

Different mechanisms operating during different critical time-windows reduce rat fetal beta cell mass due to a maternal low-protein or low-energy diet

Polymorphisms in the gene encoding the voltage-dependent Ca2+ channel CaV2.3 (CACNA1E) are associated with type 2 diabetes and impaired insulin secretion

The Pro12Ala variant at the peroxisome proliferator-activated receptor γ gene and change in obesity-related traits in the Diabetes Prevention Program

IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page